Psychiatry Research
Volume 109, Issue 1 , Pages 1-8 , 31 January 2002

Mirtazapine, but not fluvoxamine, normalizes the blunted REM sleep response to clonidine in depressed patients: implications for subsensitivity of alpha2-adrenergic receptors in depression

  • Michel Schittecatte

      Affiliations

    • Department of Psychiatry, Van Gogh Hospital, Rue de l'Hôpital, 55, B-6030 Marchienne, Belgium
    • Corresponding Author InformationCorresponding author: Tel. +32 71 29 30 07; Fax: +32 71 29 30 13
    • ,
  • Françoise Dumont

      Affiliations

    • Department of Psychiatry, Van Gogh Hospital, Rue de l'Hôpital, 55, B-6030 Marchienne, Belgium
    • ,
  • Robert Machowski

      Affiliations

    • Department of Psychiatry, Van Gogh Hospital, Rue de l'Hôpital, 55, B-6030 Marchienne, Belgium
    • ,
  • Eric Fontaine

      Affiliations

    • Department of Psychiatry, Van Gogh Hospital, Rue de l'Hôpital, 55, B-6030 Marchienne, Belgium
    • ,
  • Catherine Cornil

      Affiliations

    • Department of Psychiatry, Van Gogh Hospital, Rue de l'Hôpital, 55, B-6030 Marchienne, Belgium
    • ,
  • Julien Mendlewicz

      Affiliations

    • Department of Psychiatry, Van Gogh Hospital, Rue de l'Hôpital, 55, B-6030 Marchienne, Belgium
    • ,
  • Jean Wilmotte

      Affiliations

    • Department of Psychiatry, Van Gogh Hospital, Rue de l'Hôpital, 55, B-6030 Marchienne, Belgium

Received 10 January 2001 ,Revised 16 July 2001 ,Accepted 7 August 2001.

References 

  1. Balldin J, Berggen U, Lindstedt G, Modigh K. Neuroendocrine evidence for decreased function of alpha2-adrenergic receptor after electroconvulsive therapy. Psychiatry Research. 1992;41:257–265
  2. Bier, M.J., Greene, R.W., McCarley, R.W., 1990 Norepinephrine mediated responses in the pontine reticular formation: in vitro and in vivo studies. Abstracts, 10th Congress of the European Sleep Research Society, Strasbourg, France, p. 64.
  3. Charney DS, Heninger GR, Sternberg DE. Failure of chronic antidepressant treatment to alter growth hormone response to clonidine. Psychiatry Research. 1982;7:135–138
  4. Charney DS, Heninger GR, Sternberg DE. The effect of mianserine on alpha-2 adrenergic receptor function in depressed patients. British Journal of Psychiatry. 1984;144:407–416
  5. Claassen V. Review of the animal pharmacology and pharmacokinetics of fluvoxamine. British Journal of Pharmacology. 1983;15(Suppl 3):349S–355
  6. Coplan JD, Papp LA, Martinez J, Pine D, Rosenblum LA, Cooper T, et al. Persistence of blunted growth hormone response to clonidine in fluoxetine treated patients with panic disorder. American Journal of Psychiatry. 1995;152:619–622
  7. Corn TH, Thomson C, Checkley SA. Effects of desipramine treatment upon central adrenoceptor function in normal subjects. British Journal of Psychiatry. 1984;145:139–145
  8. De Boer TH, Ruigt GSF, Berendsen HHG. The alpha2-selective adrenoceptor antagonist Org 3770 (mirtazapine) enhances noradrenergic and serotonergic transmission. Human Psychopharmacology. 1995;10:107S–118
  9. Eriksson E, Carlson M, Nilsson C, Söderpalm B. Does alprazolam in contrast to diazepam activate alpha2 adrenoceptors involved in the regulation of growth hormone secretion?. Life Sciences. 1986;38:1491–1498
  10. Haddjeri P, Blier P, de Montigny C. Effects of long term treatment with the alpha-2 adrenoceptor mirtazapine on 5-HT neurotransmission. Naunyn-Schmiedebergs Archives of Pharmacology. 1997;355:20–29
  11. Hoehe M, Valido G, Matussek N. Growth hormone response to clonidine in endogenous depressive patients: evidence for a trait marker of depression. In:  Shagass C,  Josiassen EC,  Bridger WH,  Weiss KJ,  Stoff D,  Simpson GH editor. Biological Psychiatry. Developments in Psychiatry. Vol 7. New York: Elsevier; 1985;p. 862–864
  12. Hull CH, Nie NH. SPSS Update 7-9. New York: McGraw-Hill; 1981;
  13. Mitchell PB, Bearn JA, Checkley SA. Growth hormone response to clonidine after recovery in patients with endogenous depression. British Journal of Psychiatry. 1988;152:34–38
  14. O'Flynn K, Keane V, Dinan TG. Effects of fluoxetine on noradrenergic mediated growth hormone release: a double blind, placebo-controlled study. Biological Psychiatry. 1991;30:377–382
  15. Piletz JE, Halaris A, Ernsberger PR. Psychopharmacology of imidazoline and alpha2-adrenergic receptors: implications for depression. Critical Reviews in Neurobiology. 1994;9:29–66
  16. Putkonen PTS, Leppvuori A, Stenberg D. Paradoxical sleep inhibition by central alpha-2 adrenoceptor stimulant, clonidine, antagonized by alpha-2 receptor blocker, yohimbine. Life Sciences. 1977;21:1059–1066
  17. Schatzberg AF, Schildkraut JJ. Recent studies on norepinephrine sytems in mood disorders. In:  Bloom FE,  Kupfer DJ editor. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press; 1995;p. 911–920
  18. Schittecatte M, Charles G, Machowski R, Wilmotte J. Growth hormone response to clonidine in untreated depressed patients. Psychiatry Research. 1989;29:199–206
  19. Schittecatte M, Charles G, Machowski R, Wilmotte J. Tricyclic wash-out and growth hormone response to clonidine. British Journal of Psychiatry. 1989;154:858–863
  20. Schittecatte M, Charles G, Machowski R, Garcia-Valentin J, Mendlewicz J, Wilmotte J. Reduced clonidine REM sleep suppression in patients with primary major affective illness. Archives of General Psychiatry. 1992;49:637–642
  21. Schittecatte M, Charles G, Nefve C, Garcia-Valentin J, Machowski R, Wilmotte J. Long term downregulation of central adrenoceptor function by desipramine treatment: a clonidine study in normal subjects. Biological Psychiatry. 1992;31:856–858
  22. Schittecatte M, Charles G, Machowski R, Dumont F, Garcia-Valentin J, Wilmotte J, et al. Effects of gender and diagnosis on GH response to clonidine for major depression: a large scale multicenter study. American Journal of Psychiatry. 1994;151:216–220
  23. Schittecatte M, Garcia-Valentin J, Charles G, Machowski R, Pena-Othaitz MJ, Mendlewicz J, et al. Efficacy of the clonidine REM suppression tests to separate patients with major depression from controls: a comparison with three currently proposed biological markers of depression. Journal of Affective Disorders. 1995;33:151–157
  24. Siever LJ, Davis KL. Overview: towards a dysregulation hypothesis of depression. American Journal of Psychiatry. 1985;142:1017–1031
  25. Siever LJ, Trestman RL, Coccaro EF, Bernstein DP, Gabriel SM, Owen K, et al. The growth hormone response to clonidine in acute and remitted depressed male patients. Neuropsychopharmacology. 1992;6:165–177
  26. Siever LJ, Uhde TW, Insel TR, Roy BF, Murphy DL. Growth hormone response to clonidine unchanged by chronic clorgyline treatment. Psychiatry Research. 1982;7:139–144
  27. Spitzer RL, Endicott J. Schedule for Affective Disorders and Schizophrenia: Lifetime Version. New York: New York State Psychiatric Institute; 1978;
  28. Sugrue MF. The inability of chronic mianserine to block central alpha-2 adrenoceptors. European Journal of Pharmacology. 1980;68:377–380
  29. Svensson T, Usdin T. Feedback inhibition of brain noradrenaline neurons by tricyclic antidepressants: alpha receptor mediation. Science. 1978;202:1089–1091

PII: S0165-1781(01)00362-6

Psychiatry Research
Volume 109, Issue 1 , Pages 1-8 , 31 January 2002

Article Tools